Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) had its price objective raised by equities researchers at Royal Bank Of Canada from $112.00 to $116.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s price objective would suggest a potential downside of 4.13% from the company’s previous close.
Several other equities analysts have also issued reports on KYMR. Citigroup boosted their price target on Kymera Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a research report on Thursday. Stifel Nicolaus raised their price target on Kymera Therapeutics from $132.00 to $152.00 and gave the stock a “buy” rating in a research report on Tuesday, September 22nd. TD Cowen raised shares of Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.36.
View Our Latest Report on KYMR
Kymera Therapeutics Price Performance
KYMR stock traded down $1.61 during trading hours on Friday, reaching $120.99. 339,381 shares of the stock were exchanged, compared to its average volume of 746,757. The firm’s 50-day moving average is $114.83 and its 200-day moving average is $96.08. The company has a market cap of $10.06 billion, a price-to-earnings ratio of -37.20 and a beta of 1.98. Kymera Therapeutics has a 12 month low of $55.66 and a 12 month high of $130.05.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06). The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $3.28 million. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.94) EPS. As a group, equities research analysts forecast that Kymera Therapeutics will post -3.85 earnings per share for the current year.
Insider Buying and Selling
In other news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total value of $3,414,000.00. Following the sale, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. This trade represents a 4.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian Adams sold 6,371 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the transaction, the insider owned 50,254 shares in the company, valued at $5,871,174.82. This trade represents a 11.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 15.98% of the stock is owned by corporate insiders.
Institutional Trading of Kymera Therapeutics
A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at about $635,067,000. Merck & Co. Inc. purchased a new position in shares of Kymera Therapeutics in the second quarter worth approximately $88,544,161. Bank of America Corp DE purchased a new position in Kymera Therapeutics during the 2nd quarter valued at about $43,378,000. Bank of New York Mellon Corp bought a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at approximately $24,721,000. Finally, Eagle Health Investments LP bought a new position in shares of Kymera Therapeutics in the second quarter valued at approximately $19,052,000.
Key Headlines Impacting Kymera Therapeutics
Here are the key news stories impacting Kymera Therapeutics this week:
- Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, an oral IRF5 degrader. The drug produced deep, sustained IRF5 degradation, robust changes in disease-relevant biomarkers and a favorable safety profile in healthy volunteers, strengthening the case for continued development in immunological diseases. Kymera Announces Q3 2026 Results and KT-579 Phase 1 Data
- Positive Sentiment: Truist Securities raised its price target on KYMR to $150 from $136 while maintaining a Buy rating, signaling increased confidence in Kymera’s pipeline and potential upside. Truist Raises Kymera Price Target
- Positive Sentiment: BTIG Research also increased its target to $139 from $134 and initiated or maintained a Buy rating, adding further analyst support for the shares.
- Neutral Sentiment: The company’s Q3 earnings call focused on the financial results and KT-579 development update. Investors are likely to look for additional guidance on clinical timelines, future trials and cash resources as Kymera advances its pipeline. Kymera Q3 2026 Earnings Call Transcript
- Negative Sentiment: Kymera reported a third-quarter loss of $1.32 per share, wider than the $1.26 analyst consensus, while revenue of $1.35 million fell short of the $3.28 million estimate. The company’s negative profitability metrics and widening net loss remain risks for investors in this clinical-stage biotech. Kymera Q3 2026 Financial Results
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.
The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.
Read More
- Five stocks we like better than Kymera Therapeutics
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
- Silicon Shock: Intel’s 25% Valuation Reset
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
